Dutch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

dopamine/obesitas

De link wordt op het klembord opgeslagen
Bladzijde 1 van 49 resultaten
FIELD OF THE INVENTION 1. Field of the Invention The present invention relates to n-aryl amidines useful as D.sub.1 receptor antagonists, pharmaceutical compositions comprising the compounds, and methods of treatment using the compounds and compositions to treat obesity, metabolic disorders and CNS

(-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
1. FIELD OF THE INVENTION The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof and methods for

(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
1. FIELD OF THE INVENTION The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof and methods for

(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
1. FIELD OF THE INVENTION The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof and methods for

(-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
1. FIELD OF THE INVENTION The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof and methods for

(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
1. FIELD OF THE INVENTION The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof and methods for

Process for therapeutically modifying and resetting prolactin rhythm with a dopamine agonist

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
RELATED APPLICATIONS This is a continuation-in-part of application Ser. No. 463,327 filed Jan. 10, 1990, abandoned, which in turn is a continuation-in-part of application Ser. No. 192,332, filed May 10, 1988; both by Albert H. Meier and Anthony H. Cincotta respectively. Both applications are titled
BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like
BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like
BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like
CROSS REFERENCE TO RELATED APPLICATION This application claims the priority of Korean Patent Application No. 10-2007-0022845, filed on Mar. 8, 2007 in the KIPO (Korean Intellectual Property Office), the disclosure of which are incorporated herein in their entirety by reference. Further, this
TECHNICAL FIELD The present invention relates to a piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable salt comprising the same. BACKGROUND ART Dopamine is a neurotransmitter essential for neuronal signal transduction in animal brains including

Method for treating obesity

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
TECHNICAL FIELD The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with

Method for treating obesity

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
TECHNICAL FIELD The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with

Method for treating obesity

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
TECHNICAL FIELD The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with
Word lid van onze
facebookpagina

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

  • Werkt in 55 talen
  • Kruidengeneesmiddelen gesteund door de wetenschap
  • Kruidenherkenning door beeld
  • Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
  • Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
  • Zoek medicinale kruiden op hun effecten
  • Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek

Google Play badgeApp Store badge